Short communication: Preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects

AIDS Research and Human Retroviruses

Volumn 26, Issue 3, 2010, Pages 339-342

  Aguirre Cruz, Lucinda ^a   Torres, Klintsy J ^b   Jung Cook, Helgi ^a   Fortuny, Carlos ^b   Sánchez, Eder ^a   Soda Mehry, Antonio ^b   Sotelo, Julio ^a   Reyes Terán, Gustavo ^b  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HYDROXYCHLOROQUINE; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOID TISSUE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADENOIDS; ADMINISTRATION, ORAL; ADULT; CHEMOTHERAPY, ADJUVANT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 77950192349     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0129     Document Type: Article

References (29)

1. Hazenberg MD, Otto SA, van Rossum AM, et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17:1881-1888.
2. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV-infection. Nature Med 2006;12:1365-1371.
3. Pomerantz RJ: Reservoirs, sanctuaries, and residual disease: The hiding spots of HIV-1. HIV Clin Trials 2003;4: 137-143.
4. Guadalupe M, Sankaran S, George MD, et al.: Viral suppression and immune restoration in the gastrointestinal mucosa of HIV type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006;80:8236-8247.
5. Zhang L, Ramratnam B, Tenner-Racz K, et al.: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340: 1605-1613.
6. Lori F: Treating HIV=AIDS by reducing immune system activation: The paradox of immune deficiency and immune hyperactivation. Curr Opin HIV AIDS 2008;3:99-103.
7. Hoekenga MT: The treatment of malaria with hydroxychloroquine. Am J Trop Med 1955;4:221-223.
8. Mackenzie AH and Scherbel AL: Chloroquine and hydroxychloroquine in rheumatological therapy. Clin Rheum Dis 1980;6:545-566.
9. Felson DT, Anderson JJ, and Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990;33:1449-1458.
10. Petri M, Lakatta C, Magdre L, et al.: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med 1994;96:254-259.
11. Fox RI: Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993;2(Suppl 1): 82-91.
12. Goldman FD, Gilman AL, Hollenback C, et al.: Hydroxychloroquine inhibits calcium signals in T cells: A new mechanism to explain its immunomodulatory properties. Blood 2000;95:3460-3466.
13. Naarding MA, Baan E, Pollakis G, et al.: Effect of chloroquine on reducing HIV-1 replication in vitro and the DCSIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology 2007;4:6. doi:10.1186=1742-4690-4-6.
14. Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, and Sperber K: Inhibition of HIV-1 replication by hydroxychloroquine: Mechanism of action and comparison with zidovudine. Clin Ther 1996;18(6):1080-1092.
15. Paton NI and Aboulhab J: Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: Safety, efficacy and resistance profile after 144 weeks. HIV Med 2005;6:13-20.
16. Yousem DM, Loevner LA, Tobey JD, Geckle RJ, Bilker WB, and Chalian AA: Adenoidal width and HIV factors. AJNR Am J Neuroradiol 1997;18:1721-1725.
17. Tapanes RD, Ramos F, and Pérez Avila J: Contribution to the determination of chloroquine in biological fluids. J Chromatogr 1989;493(1):196-201.
18. Minzi OM, Rais M, Svensson JO, Gustafsson LL, and Ericsson O: High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783(2):473-480.
19. McLachlan AJ, Tett SE, Cutler DJ, et al.: Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. Br J Rheumatol 1994;33:235-239.
20. Munster T, Gibbs JP, Shen D, et al.: Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1460-1469.
21. Carmichael S, Bruce Ch, and Tett S: Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 2003;25:671-681.
22. Tett SE, Cutler DJ, Day RO, et al.: A dose ranging study or the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1998;26:303-313.
23. Savarino A, Gennero L, Chen H, et al.: Anti-HIV effects of chloroquine: Mechanisms of inhibition and spectrum of activity. AIDS 2001;15:2221-2229.
24. Savarino A, Boelaert JR, Cassone A, et al.: Effects of chloroquine on viral infections: An old drug against today's diseases? Lancet Infect Dis 2003;3:722-727.
25. Tsai WP, Nara PL, Kung HF, et al.: Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990;6:481-489.
26. Appay V and Sauce D: Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol 2008;214:231-241.
27. HCQ-01 Trial: Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic human immunodeficiency virus (HIV) infected patients. ISRCTN30019040. Accessed at http:==www.controlled-trials .com=ISRCTN30019040=hydroxychloroquine.
28. Nilsson J, Kinloch-de-Loes S, Granath A, Sönnerborg A, Goh LE, and Andersson J: Early immune activation in gutassociated and peripheral lymphoid tissue during acute HIV-infection. AIDS 2007;21(5):565-574.
29. Yasuda H, Leelahavanichkul A, Tsunoda S, et al.: Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 2008;294:F1050-F1058.